Dashboard
Manage Tickers

TGTX TG THERAPEUTICS, INC.

Nasdaq tgtherapeutics.com


$ 30.35 $ -1.95 (-6.04 %)    

Monday, 10-Nov-2025 15:57:59 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 623.47 $ 4.68 (0.76 %)
DIA $ 473.70 $ 1.85 (0.39 %)
SPY $ 681.46 $ 4.28 (0.63 %)
TLT $ 89.54 $ 0.05 (0.06 %)
GLD $ 378.13 $ 2.19 (0.58 %)
$ 32.24
$ 32.29
$ 30.33 x 100
$ 30.35 x 300
$ 29.84 - $ 32.29
$ 25.28 - $ 46.48
1,762,403
na
5.12B
$ 1.77
$ 11.44
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-08-2025 06-30-2025 10-Q
3 05-09-2025 03-31-2025 10-Q
4 03-03-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-09-2024 06-30-2024 10-Q
7 05-06-2024 03-31-2024 10-Q
8 02-29-2024 12-31-2023 10-K
9 11-06-2023 09-30-2023 10-Q
10 08-04-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 03-01-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-08-2021 09-30-2021 10-Q
18 08-06-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-02-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-09-2019 06-30-2019 10-Q
27 05-10-2019 05-10-2019 10-Q
28 03-01-2019 12-31-2018 10-K
29 11-09-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-15-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-16-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-10-2016 03-31-2016 10-Q
40 03-15-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
10 Health Care Stocks Whale Activity In To...
11/03/2025 17:35:20

jp-morgan-maintains-overweight-on-tg-therapeutics-raises-price-target-to-49
JP Morgan Maintains Overweight on TG Thera...
11/03/2025 15:58:47

JP Morgan analyst Eric Joseph maintains TG Therapeutics (NASDAQ:TGTX) with a Overweight and raises the price target from $46...

top-stocks-with-earnings-this-week-joby-ionq-amd-and-more
Top Stocks With Earnings This Week: Joby, ...
11/03/2025 14:14:07

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Fr...

tg-therapeutics-raises-fy2025-sales-guidance-from-585000m-to-600000m-vs-588045m-est
TG Therapeutics Raises FY2025 Sales Guidan...
11/03/2025 12:03:20

TG Therapeutics (NASDAQ:TGTX) raises FY2025 sales outlook from $585.000 million to $600.000 million vs $588.045 million estimate.

tg-therapeutics-q3-eps-243-beats-022-estimate-sales-161709m-beat-152169m-estimate
TG Therapeutics Q3 EPS $2.43 Beats $0.22 E...
11/03/2025 12:02:03

TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $2.43 per share which beat the analyst consensus estimate of $0.22...

earnings-scheduled-for-november-3-2025
Earnings Scheduled For November 3, 2025
11/03/2025 11:11:31

earnings-preview-for-tg-therapeutics
Earnings Preview For TG Therapeutics
10/31/2025 19:01:17

tg-therapeutics-completes-enrollment-in-phase-3-enhance-trial-evaluating-simplified-dosing-schedule-for-briumvi
TG Therapeutics Completes Enrollment In Ph...
10/28/2025 11:32:16

small-cap-biotech-climb-bios-lead-drug-candidate-has-larger-long-term-opportunity
Small-Cap Biotech Climb Bio's Lead Drug Ca...
10/16/2025 17:40:28

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...

ihc-wainwright--co-assumes-tg-therapeutics-at-buy-announces-price-target-of-60
IHC Wainwright & Co. Assumes TG Therapeuti...
10/06/2025 10:47:28

HC Wainwright & Co. analyst Emily Bodnar assumes TG Therapeutics (NASDAQ:TGTX) with a Buy rating and announces Price Tar...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/01/2025 17:35:33

tg-therapeutics-reports-near-zero-relapse-rate-after-6-years-of-briumvi-treatment-in-multiple-sclerosis-with-no-new-safety-signals
TG Therapeutics Reports Near-Zero Relapse ...
09/24/2025 13:12:08

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring e...

b-riley-securities-maintains-buy-on-tg-therapeutics-raises-price-target-to-55
B. Riley Securities Maintains Buy on TG Th...
09/17/2025 18:12:00

B. Riley Securities analyst Mayank Mamtani maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target fr...

tg-therapeutics-to-present-long-term-briumvi-data-in-relapsing-ms-at-ectrims-2025-including-six-year-ultimate-i--ii-results-and-real-world-enable-study-updates
TG Therapeutics To Present Long-Term BRIUM...
09/10/2025 11:36:36

tg-therapeutics-to-present-long-term-briumvi-data-in-relapsing-ms-at-ectrims-2025-including-six-year-ultimate-i--ii-results-and-real-world-enable-study-updates
TG Therapeutics To Present Long-Term BRIUM...
09/10/2025 11:33:25

tg-commenced-enrollment-phase-3-trial-for-subcutaneous-briumvi
TG Commenced Enrollment Phase 3 Trial For ...
09/08/2025 11:30:41

tg-therapeutics-ceo-voices-strong-conviction-in-briumvi-with-new-100-million-buyback
TG Therapeutics CEO Voices Strong Convicti...
09/03/2025 16:40:49

TG Therapeutics' stock rose after completing a $100 million buyback and approving another $100 million plan, reinforcing co...

tg-therapeutics-authorizes-new-100m-repurchase-program
TG Therapeutics Authorizes New $100M Repur...
09/03/2025 11:31:56

tg-therapeutics-files-for-mixed-shelf-offering-size-not-disclosed
TG Therapeutics Files For Mixed Shelf Offe...
08/08/2025 21:27:30

-SEC Filing

crude-oil-falls-15-on-semiconductor-shares-plunge-after-q2-results
Crude Oil Falls 1.5%; ON Semiconductor Sha...
08/04/2025 17:33:21

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION